Streetbeat News

MGX

Metagenomi Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

3.34

Mkt cap

113M

Volume

17M

High

4.00

P/E Ratio

-1.35

52-wk high

12.74

Low

2.94

Div yield

N/A

52-wk low

1.61

Metagenomi, Inc. (Nasdaq: MGX) has announced significant progress in its therapeutic portfolio, including advancements in MGX-001 for Hemophilia A and anticipated milestones for 2025. The company is on track for regulatory interactions and development candidate nominations, with a cash runway supporting operations into 2027.

Portfolio Pulse from

January 16, 2025 | 2:15 pm

Levi & Korsinsky has announced a class action lawsuit against Metagenomi, Inc. (NASDAQ:MGX) with a lead plaintiff deadline of November 25, 2024. Investors who suffered losses are encouraged to seek potential recovery under federal securities laws.

Portfolio Pulse from

November 26, 2024 | 12:45 am

Levi & Korsinsky has filed a securities class action lawsuit on behalf of Metagenomi, Inc. (NASDAQ:MGX) shareholders. Investors who suffered losses can seek potential recovery under federal securities laws.

Portfolio Pulse from

November 25, 2024 | 11:30 pm

Pomerantz Law Firm has filed a class action lawsuit against Metagenomi, Inc. (NASDAQ: MGX). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 25, 2024 | 11:00 pm

Levi & Korsinsky has notified investors of Metagenomi, Inc. (NASDAQ:MGX) about a class action lawsuit. Investors who suffered losses can seek potential recovery under federal securities laws.

Portfolio Pulse from

November 25, 2024 | 9:45 pm

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Metagenomi, Inc. (NASDAQ: MGX) and certain officers, offering investors with substantial losses the opportunity to lead the lawsuit.

Portfolio Pulse from

November 25, 2024 | 9:15 pm

Metagenomi, Inc. (NASDAQ:MGX) is facing a lawsuit for securities law violations. Investors who suffered losses are encouraged to contact Levi & Korsinsky before November 25, 2024, to discuss potential recovery options.

Portfolio Pulse from

November 25, 2024 | 8:15 pm

A class action lawsuit has been filed against Metagenomi, Inc. (NASDAQ:MGX) for potential securities law violations. Investors who suffered losses are encouraged to join the lawsuit by November 25, 2024.

Portfolio Pulse from

November 25, 2024 | 5:00 pm

Metagenomi, Inc. is facing a class action lawsuit filed by The Schall Law Firm for alleged violations of federal securities laws related to its IPO. Shareholders with losses are urged to contact the firm.

Portfolio Pulse from

November 25, 2024 | 4:45 pm

Rosen Law Firm is urging investors in Metagenomi, Inc. (NASDAQ: MGX) to secure legal counsel before the November 25, 2024 deadline for a securities class action related to the company's IPO.

Portfolio Pulse from

November 25, 2024 | 4:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.